The five-day extradition trial of fugitive diamond merchant Nirav Modi will begin from May 11 in a part-remote setting, a UK court has ordered.
Modi is fighting his extradition to India over the nearly $2 billion Punjab National Bank (PNB) fraud and money laundering case.
The 49-year-old, who has been lodged at Wandsworth Prison in south-west London since his arrest last year, appeared before the court via video conferencing due to the social distancing procedures put in place across the UK courts in view of the COVID-19 pandemic.
He spoke only to confirm his name and date of birth during the hearing, which took place at Westminster Magistrates' Court in London.
District Judge Samuel Goozee, who presided over the case management hearing, expressed some reservations about the extradition hearing going ahead next month as scheduled under the current lockdown.
But it was agreed between all the parties that a trial run of the court's CVP (Common Viewing Platform) will take place during a lawyers-only hearing on May 7 ahead of the final hearing.
"Some prisons are producing prisoners in person, so I will direct Wandsworth Prison to produce Mr Modi in person for the trial from May 11. If that is not practicable, his participation by live link remains a backstop," Judge Goozee concluded.
It was agreed that a limited number of legal representatives will be present physically in court for the trial as witnesses give their evidence via videolink. Modi will be able to observe the proceedings either from the dock, if the prison authorities agree to a physical transfer, or via the judiciary's common viewing system from Wandsworth Prison.
The five-day hearing from May 11 relates to the Indian government’s extradition request certified by the UK government last year.
The case, filed by the Central Bureau of Investigation (CBI) and the Enforcement Directorate (ED), relates to a large-scale fraud upon an Indian Public Sector Undertaking (PSU) through the fraudulent obtaining of letters of understanding (LoUs) and the laundering of the proceeds of that fraud.
Two additional charges of "causing the disappearance of evidence" and intimidating witnesses or “criminal intimidation to cause death” were added on by the CBI and certified earlier this year.
“The May 11 extradition hearing is going ahead and the new request (two additional offences part of the CBI case) has not been joined but will be dealt with at a separate later hearing, probably in July,” said the Crown Prosecution Service (CPS), appearing on behalf of the Indian authorities.
CPS barrister Nick Hearn indicated that the government of India's representatives would be following the proceedings and giving instructions via the court's online common viewing platform, given the coronavirus related travel restrictions.
“We have received comprehensive responses in writing from the government of India, which would reduce the likely length of cross-examinations,” said Hearn.
It was also confirmed that the diamond merchant would not be giving evidence in the case, but his legal team plans to produce around six witnesses, including a jewellery expert as well as judicial and prisons experts.
“We are very anxious to hold the hearing if we can, if Mr Modi’s participation and that of the witnesses seems feasible,” said Modi’s barrister Clare Montgomery, during the tele-conference hearing on Tuesday.
Judge Goozee has set May 4 as the deadline for the skeleton arguments, draft charges and any further evidence to be presented in the case.
In reference to the "wealth of documentary evidence relied on in the case", he has sought an agreed pre-trial reading list by the end of this week.
Most of the legal cases in the UK have incorporated videolink and telephonic options where possible, with all new jury trials suspended amid the social distancing rules in place to combat the coronavirus pandemic.
Modi, whose Wandsworth prison is considered one of the most over-crowded in England, made a fifth attempt at bail in the High Court last month, which was rejected as the judge ruled that he continued to pose a flight risk.
He was arrested on March 19, 2019, on an extradition warrant executed by Scotland Yard on charges of fraud and money laundering brought in by the Indian government.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.